1 Brief Communication:

2 The role of M1 to M2 macrophage polarization in the etiology of idiopathic gastroparesis:

3 GWAS perspective

- 4 Sandra P. Smieszek Ph.D., Jesse L. Carlin Ph.D., Changfu Xiao, Christos M. Polymeropoulos,
- 5 Gunther Birznieks, Mihael H. Polymeropoulos, MD
- ⁶ ¹Vanda Pharmaceuticals Inc., 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037

7 corresponding author: sandra.smieszek@vandapharma.com

8

9 Abstract

10

11 Gastroparesis is a serious medical condition characterized by delayed gastric emptying and

12 symptoms of nausea, vomiting, bloating, fullness after meals, and abdominal pain. An innate

immune dysregulation and injury to the interstitial cells of Cajal and other components of the

14 enteric nervous system are likely central to the pathogenesis of gastroparesis. Thus far, little is

known about the underlying genetic risk factors for gastroparesis. To ascertain these genetic risk
 factors for gastroparesis we conducted the first large whole-genome sequencing genome-wide

factors for gastroparesis we conducted the first large whole-genome sec
 association study (GWAS) analysis of gastroparesis patients.

18 The GWAS focused on idiopathic and diabetic gastroparesis cases as compared to matched

19 controls as well as compared idiopathic versus diabetic cases. Amongst the top variants, we

20 report a novel genetic risk variant for idiopathic gastroparesis - genetic association of the *Solute*

21 *Carrier Family 15 (SLC15)* locus. This signal is driven by multiple variants with top missense

22 variant SLC15A4:NM145648:exon2:c.T716C:p.V239A, rs33990080. SLC15A4 was shown to

23 mediate M1-prone metabolic shifts in macrophages and guards immune cells from metabolic

24 stress. The risk variant carriers have a significantly higher nausea score at baseline. We also

25 delineated a number of statistically significant loci including novel ones as well as previously

26 known loci such as *HLA-DQB1* - rs9273363, variant associated with Type 1 diabetes..

27 The GWAS picture that is emerging implicates the role of the machinery of M1 to M2

28 macrophage polarization in the etiology of idiopathic gastroparesis. We suggest that macrophage

29 polarization fate could lead to the destruction of the interstitial cells of Cajal which effectively

- 30 leads to abnormal gastric emptying.
- 31
- 32

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33

34 Introduction

35

- 36 Gastroparesis is a serious medical condition characterized by delayed gastric emptying in the
- absence of mechanical obstruction¹. The main symptoms include nausea, vomiting, bloating,
- fullness after meals, and abdominal pain¹. The overall standardized prevalence of gastroparesis is
- 267.7 per 100,000 US adults, whereas the prevalence of "definite" gastroparesis is 21.5 per
- 40 $100,000^{2}$. Common etiologies include diabetes, post-surgical gastroparesis and idiopathic
- 41 gastroparesis (with estimates of idiopathic (~11.3%) vs diabetic (>51.7%))².
- 42 An innate immune dysregulation and injury to the interstitial cells of Cajal (ICC) and other
- 43 components of the enteric nervous system through paracrine and oxidative stress mediators are
- 44 likely central to the pathogenesis of gastroparesis³. Loss of antral CD206 positive anti-
- inflammatory macrophages is a key feature in human gastroparesis and it associates with ICC
- 46 loss⁴. A review of the literature suggests that oxidative stress associated with diabetes activates
- 47 macrophages. Activation of CD206 +, anti-inflammatory M2 macrophages expressing heme
- 48 oxygenase 1 (HO1) is protective while activation of pro-inflammatory M1 macrophages which
- 49 lack HO1 is injurious and leads to the development of delay in gastric emptying³⁵. Low numbers
- of M2 macrophages were correlated with loss of ICC and were associated with both idiopathic and diabetic gastroparesis⁴. Importantly, when the anti-inflammatory M2 macrophages were
- and diabetic gastroparesis⁴. Importantly, when the anti-inflammatory M2 macrophages were switched to pro-inflammatory M1 macrophages, delayed GE was evident in animal models⁴.
- 53 Consistent with this notion is gastroparesis in patients receiving immune checkpoint inhibitors –
- 54 blockage to PD-1/PD1-L and the resultant damage to the anti-inflammatory macrophages⁶. It is
- plausible that the blockage of PD-1/PD-L1 by ICI contributes to the onset of gastroparesis as a
- result of an immune-related adverse event. This is consistent with the decreased production of
- 57 protective cytokines by M2 macrophages which was shown in acute lung injury with the
- 58 blockage of PD-1/PD1- L^6 .

59

- 60 Thus far, there little is known regarding the common genetic risk factors for idiopathic
- 61 gastroparesis. Prior studies reported Longer poly-GT repeats in the HMOX1 gene are more
- 62 common in African Americans with gastroparesis, particularly in patients with diabetes⁷. To
- ascertain the genetic risk factors for gastroparesis we conducted a large whole-genome
- 64 sequencing (WGS) of samples obtained from well clinically characterized gastroparesis studies
- of both diabetic and idiopathic gastroparesis. We have done a GWAS comparing idiopathic and
- diabetic cases with controls as well l as a GWAS on idiopathic versus with diabetic cases. We
- 67 have delineated the expected loci in the diabetic gastroparesis cohort and furthermore, we report
- 68 novel associations with the idiopathic gastroparesis.
- 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84

85 **Results**

86

87 Whole-genome sequencing was done on 1385 samples obtained from consented gastroparesis patients. Samples were obtained from patients participating in two gastroparesis studies phase II 88 clinical study (VP-VLY-686-2301 and ongoing phase III gastroparesis clinical study (VP-VLY-89 686-3301). Inclusion criteria included patients with idiopathic or diabetic gastroparesis with 90 moderate to severe nausea, delayed gastric emptying, daily 50% worst average nausea score ≥ 3 91 and GCSI nausea score \geq 3 at screening. In the phase III study subjects included male and female 92 93 adults ages 18-70 with a diagnosis of diabetic or idiopathic gastroparesis. Subjects enrolled in the study had evidence of delayed gastric emptying, and moderate to severe nausea, daily average 94 nausea score of > 2.5, at least one episode of vomiting, PAGI-SYM nausea score of ≥ 2 at 95 screening, and controlled blood glucose levels with HbA1c < 10%. Demographics and clinical 96 97 characteristics are provided in Table 1. Self-reported ancestry was further confirmed with Principal Component Analysis (PCA) - details provided in the Methods section. Association 98 99 results were obtained from logistic models for the 4 following GWAS analyses: idiopathic vs. 100 controls, diabetic vs. controls, gastroparesis cases vs. non gastroparesis matched controls and

101 diabetic vs. idiopathic cases.

102 Idiopathic Gastroparesis

103 To avoid spurious signals resulting from population substructure, the largest set of EUR ancestry

- 104 was used for the purpose of the idiopathic and diabetic analyses. The analysis consisted of
- variants with Minor Allele Frequency (MAF) >1, EUR individuals (PCA-defined) in both cases
- 106 (n=319) and controls (n=896). For comparisons of variant frequencies, we used both
- 107 gastroparesis cohorts, controls and $gnomAD^8$ (matched by ancestry as defined by PCA). Cases
- and controls were called by uniform GATK pipeline, with only variants passing GATK's Variant
- 109 Quality Score Recalibration (VQSR) and internal MAF cutoffs were analyzed. Amongst the
- top strongest loci is a signal from variant within the Solute carrier family 15 (SLC15A4) gene -
- 111 lead variant rs10847696 (*p*-value<0.000004 (OR:1.9). The non-synonymous variant of interest,
- NM145648:exon2:c.T716C:p.V239A, rs33990080 is also depicted on the Manhattan plot Figure
 1A and the SLC15A4 regional zoom plot Figure 2. We report 69 carriers among 214 idiopathic
- patients versus 165 out of 896 ancestry-matched controls (MAF: cases 0.18; MAF: controls 0.09)
- and OR: 1.9. The MAF of the top coding variant among all gastroparesis patients, combining
- both diabetic and idiopathic patients is 0.16. The global MAF among non-finnish-europeans
- (NFE) in a public database (gnomAD⁸) is 0.09. The significant effect persists when idiopathic
- 118 cases are compared with diabetic cases as the MAF of diabetic cases (0.10) is comparable to that
- of population controls (0.09). The variant is a highly statistically significant (*p*-value< 10^{-17})
- 120 eQTL for chr12 *GLT1D1* and *SLC15A4* (GTEX⁹) **Supplementary Figure 1A**. The identified
- variant carriers have a significantly higher nausea score at baseline with a mean difference ~ 0.3
- 122 unit, and ~0.6 unit if comparing homozygotes (*p*-value<0.04) as shown on **Supplementary**
- **Figure 1B**. There are additional significant variants reported within *SLC15A4* gene in
- association with idiopathic gastroparesis further supporting the effect carried by identified
- region. The top results for the idiopathic vs. controls analysis are presented in **Table 2** as well as
- 126 in the **Supplementary Material Data.** Other identified loci include intergenic variants in the
- region of *MIR8054* and *LUZP2* genes as well as other loci depicted in Table 2. Importantly, we

- have furthermore replicated the effect of this SLC15A4 variant in another batch of EUR
- 129 gastroparesis samples with OR 1.6 *p*-value<10^5.
- 130
- 131 Diabetic vs. Idiopathic Gastroparesis

Whereas the primary focus of this analysis was on idiopathic rather than diabetic gastroparesis, 132 both sets of analysis vielded informative results. In this set idiopathic controls are super controls 133 as this is a set with a confirmed negative diabetes diagnosis. Top variants in diabetic 134 gastroparesis GWAS included variants pointing to HLA-DQB1 with lead variant rs9275638. 135 Among the reported top variants is rs9273363 - a known risk factor for Type 1 diabetes, with an 136 OR of 2.1, *p*-value $<10^{-5}$, a common variant with a MAF of 0.39 in diabetic gastroparesis cases 137 versus MAF of 0.22 in idiopathic controls as well as MAF 0.27 in matched EUR controls. The 138 variant is tagging the HLA DQB1*03:02 haplotype and the 6q22.33 region, which contains the 139 genes encoding protein tyrosine phosphatase receptor k (PTPRK). Amongst the other top 140 variants are loci within EXOC6B depicted in Figure 1B and Table 3. EXOC6B's top variant is a 141 UTR variant rs41416 highly increased among diabetic but not idiopathic cases (OR 3.3, p-142 *value* $< 10^{-7}$). This exocyst complex gene has been previously associated with increased risk of 143 Type II diabetes. We have furthermore calculated a T2D polygenetic risk score to see how well 144 we can cluster cases. Polygenic scores were constructed for diabetes by summing the number of 145 risk alleles carried by each individual, weighted by the effect size estimates from well-146 established genome-wide significant associations derived from Li et al., 2021 (60 SNPs)¹⁰. We 147 differentiate idiopathic from diabetic gastroparesis with a diabetes genetic risk score, -148 statistically significant result (*p*-value<0.0004). This reinforces the capacity to subgroup cases 149 based on diabetes risk score. This is presented in the Supplementary Material Figure 2 150 151 Additionally, we explored the frequencies of previously reported variants in a functional dyspepsia GWAS¹¹. Two variants previously reported came out as nominally significant: 152 rs2595968 (NFASC *p*-value<0.004) and rs17597505 (*p*-value<0.03). 153 154

155

156 Discussion

- 157
- 158 Whole-genome sequencing can provide unique insights into genetic determinants of
- 159 gastroparesis, by uncovering associations between common as well as rare genetic variants. Such
- loci can be extremely helpful, because they are often coding, thereby pointing directly to a causal
- 161 gene. In this study focused primarily on idiopathic and diabetic gastroparesis cases. We report
- 162 novel variants associated with idiopathic gastroparesis as well as known risk factors previously
- associated with diabetes. Importantly, we report a novel genetic association of the *SLC15A4*
- 164 (p.Val239Ala) risk variant conferring a greater risk of idiopathic gastroparesis.

Solute carrier family 15 (SLC15) A4 is a lysosome-resident, amino acid/oligopeptide transporter 165 that is preferentially expressed in immune cells¹². This proton-coupled amino-acid transporter 166 mediates the transmembrane transport of L-histidine and some di- and tripeptides from inside the 167 lysosome to the cytosol, and plays a key role in innate immune responses. Importantly, it is 168 required for TLR7/9-dependent type I interferon production¹³. SLC15A4 has been associated 169 with disorders such as inflammatory bowel diseases and systemic lupus erythematosus¹³,¹⁴. High 170 levels of *SLC15A4* transcripts were observed in human antigen-presenting cells, including 171 dendritic cells, activated macrophages, and B cells¹³. SLC15A4 was shown to mediate M1-prone 172 metabolic shifts in macrophages and guards immune cells from metabolic stress¹². SLC15A4 173 loss disturbed the coupling of glycolysis and the TCA cycle, and SLC15A4-deficient 174 macrophages preferred to use glutamine rather than glucose as a carbon source for the TCA 175 cycle¹². SLC15A4-deficient macrophages produced low levels of itaconate and proinflammatory 176 IL-12 cytokine members. Correspondingly, $SLC15A4^{-/-}$ mice developed a less severe form of 177 Th1-dependent colitis than $SLC15A4^{+/+}$ mice¹³. SLC15A4 was shown to promote colitis through 178 Toll-like receptor 9 and NOD1-dependent innate immune responses. It is involved in 179 180 maintaining the histidine homeostasis within intracellular compartments and is crucial for eliciting effective innate immune responses. SLC15A4-intact but not SLC15A4-deficient 181 macrophages became resistant to fluctuations in environmental nutrient levels by limiting the use 182 of the glutamine source; thus, SLC15A4 was critical for macrophage's respiratory homeostasis¹². 183

184 Previous reports have shown that when the anti-inflammatory M2 macrophages are switched to

pro-inflammatory M1 macrophages, delayed GE was evident in animal models ⁴. This is

consistent with the GWAS picture that is emerging where the machinery of M1 to M2

187 macrophage polarization seems to be implicated. These findings suggest a mechanism of

188 metabolic regulation in which an amino acid transporter acts as a gatekeeper that protects

immune cells' ability to acquire an M1-prone metabolic phenotype in inflammatory tissues by
 mitigating metabolic stress. It seems the detected loci could be directly connected to macrophage

190 mitigating metabolic stress. It seems the detected loci could be directly connected to macrophage 191 polarization either via gain of function of hyperexpression, mechanisms that still need to be

192 confirmed. Past reports on idiopathic cases suggested a reduction in both myenteric and

intramuscular interstitial cells of Cajal at the center of the etiology of gastroparesis¹⁵. Successful

194 gastric emptying results from the successful cooperation between smooth muscle, enteric and

autonomic nerves, and ICC^{15} . It may be the case that multiple paths lead to the same aberrant

196 pathway such as in the M1/M2 macrophage polarization leading to gastroparesis, both of the

197 diabetic or idiopathic etiology. In this report, we show such potential risk factors from a genetic

198 perspective. We suggest that macrophage polarization fate could lead to the destruction of the

199 interstitial cells of Cajal effectively leads to abnormal gastric emptying.

Nevertheless, our findings despite initial replication require further confirmation as the number of sequenced cases increases. Large association studies require careful control for population stratification and hence analysis was focused on EUR samples. Further analyses are necessary across other ancestries. There are other variants delineated in this study that call for further confirmation and research into their mechanisms of action. By depleting the diabetic cases and doing a sub-analysis we created a homogenous set for exploratory GWAS. We successfully

206 detected risk for HLA-DQB1 – in the diabetes cohort - we also identified other loci that call for

- further confirmatory studies such as EXOC6B. Despite this being the largest WGS study
 reported, size is still a limitation and further replication of these findings will be necessary.
- In summary, we detected novel loci associated with idiopathic gastroparesis. We also
- reproduced a genome-wide significant signal for diabetic gastroparesis a whole-genome-wide
- significant association between HLA-DQB1 and Type 1 diabetic gastroparesis amongst other
- variants. Our results also suggest an association between macrophage polarization at the center
- of the etiology of idiopathic gastroparesis, a mechanism that has also been implicated in the
- etiology of gastroparesis in patients with diabetes. Future genome-wide studies of rare variants
- will require a larger sample size to fully understand the genetic architecture of gastroparesis.,
- 216
- 217
- 218
- 219
- 219
- 220
- 221
- 222
-
- 223
- 224
- 225
- 226
- 227
- 228
- 229

230 Methods:

231 Datasets

- Samples were obtained from patients participating in two respective gastroparesis clinical trials
- phase II clinical study VP-VLY-686-2301¹⁶ and phase III clinical study VP-VLY-686-3301.
- Inclusion criteria for both studies included patients with idiopathic or diabetic gastroparesis with
- moderate to severe nausea and delayed gastric emptying, as well as controlled diabetes status.
 The first gastroparesis dataset (phase II clinical study VP-VLY-686-2301) was a multiethnic
- cohort $(n 119)^{16}$. This cohort was composed of 90.7% females; the average age was 45.9; 86.2%
- of the patients self-identified as White, 10.5% self-reported as Black or African American, 2%
- self-reported American Indian or Alaska Native and 1.3% reported as Asian. The second study
- 240 (VP-VLY-686-3301) was a multiethnic cohort composed of 70.2% females; the average age was

- 241 48.5; 64.5% of the patients self-identified as White, 31.7% self-reported as Black or African
- 242 American, 0.8% self-reported American Indian or Alaska Native and 1.9% reported as Asian.
- 243

Genetic analysis 244

DNA samples were quantified using fluorescent-based assays (PicoGreen) to accurately 245

- 246 determine whether sufficient material is available for library preparation and sequencing. DNA
- sample size distributions were profiled by a Fragment Analyzer (Advanced Analytics) or 247
- BioAnalyzer (Agilent Technologies), to assess sample quality and integrity. WGS libraries were 248
- 249 prepared using the Truseq DNA PCR-free Library Preparation Kit. Whole Genome data were
- processed on NYGC automated pipeline. Paired-end 150 bp reads were aligned to the GRCh37 250
- human reference (BWA-MEM v0.7.8) and processed with GATK best-practices workflow 251
- 252 (GATK v3.4.0). The mean coverage was 35.8reflecting the average of the samples. All highquality variants obtained from GATK pipeline were functionally annotated (intronic, intergenic,
- 253
- splicing, nonsynonymous, stopgain and frameshifts) based on RefSeq transcripts. Cases and 254
- 255 controls were called with the sample pipeline, only variants passing GATK's Variant Quality
- Score Recalibration VQSR) internal MAF cutoff were included in the analysis. 256
- 257
- 258
- 259
- 260
- 261 **GWAS**

We performed a GWAS using variants with minor allele frequencies higher than 1% and allele 262

- count of 10 or more, with the same analysis design used in the landmark COVID-19 HGI 263
- GWAS¹⁷. We performed single variant association tests using a GWAS additive model 264
- framework. Logistic models adjusted for PC, age and sex were conducted in PLINK¹⁸. The 265
- analysis was limited to individuals of European (EUR) genetic ancestry due to the largest cohort 266
- available in this ancestry and in order to avoid confounders in the form of population 267
- substructure. The Principal Component Analysis and PC definitions are based on the one 268
- 269 provided by the COVID-19 Host Genetics Initiative, available here for
- 270 reference: https://github.com/covid19-hg/pca_projection. A common set of SNPs was used for
- ancestry definitions to match those for 1000 genomes project (V3). 271
- 272
- 273

References 274

- 275
- Camilleri M, Chedid V, Ford AC, et al. Gastroparesis. Nature reviews Disease primers. 276 1. 2018;4(1):41. doi:10.1038/s41572-018-0038-z 277
- Ye Y, Yin Y, Huh SY, Almansa C, Bennett D, Camilleri M. Epidemiology, Etiology, and 278 2.

279 280		Treatment of Gastroparesis: Real-World Evidence From a Large US National Claims Database. <i>Gastroenterology</i> . 2022;162(1):109-121.e5. doi:10.1053/j.gastro.2021.09.064
281 282	3.	Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. <i>Gut.</i> 2019;68(12):2238-2250. doi:10.1136/gutjnl-2019-318712
283 284 285 286	4.	Grover M, Bernard CE, Pasricha PJ, et al. Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. <i>Neurogastroenterology and motility</i> : <i>the official journal of the European Gastrointestinal Motility Society</i> . 2017;29(6). doi:10.1111/nmo.13018
287 288 289	5.	Neshatian L, Gibbons SJ, Farrugia G. Macrophages in diabetic gastroparesisthe missing link? <i>Neurogastroenterology and motility</i> : <i>the official journal of the European Gastrointestinal Motility Society</i> . 2015;27(1):7-18. doi:10.1111/nmo.12418
290 291 292	6.	Atieh J, Sack J, Thomas R, Rahma OE, Camilleri M, Grover S. Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series. <i>Digestive diseases and sciences</i> . 2021;66(6):1974-1980. doi:10.1007/s10620-020-06440-x
293 294 295	7.	Gibbons SJ, Grover M, Choi KM, et al. Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. <i>PloS one</i> . 2017;12(11):e0187772. doi:10.1371/journal.pone.0187772
296 297 298	8.	Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. <i>bioRxiv</i> . August 2019:531210. doi:10.1101/531210
299 300	9.	Lonsdale J, Thomas J, Salvatore M, et al. The Genotype-Tissue Expression (GTEx) project. <i>Nature Genetics</i> . 2013;45(6):580-585. doi:10.1038/ng.2653
301 302 303	10.	Li JH, Szczerbinski L, Dawed AY, et al. A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas. <i>Diabetes</i> . 2021;70(1):293-300. doi:10.2337/db20-0530
304 305 306 307	11.	Garcia-Etxebarria K, Carbone F, Teder-Laving M, et al. A survey of functional dyspepsia in 361,360 individuals: Phenotypic and genetic cross-disease analyses. <i>Neurogastroenterology and motility</i> : <i>the official journal of the European</i> <i>Gastrointestinal Motility Society</i> . 2022;34(6):e14236. doi:10.1111/nmo.14236
308 309 310 311	12.	Kobayashi T, Nguyen-Tien D, Sorimachi Y, et al. SLC15A4 mediates M1-prone metabolic shifts in macrophages and guards immune cells from metabolic stress. <i>Proceedings of the National Academy of Sciences</i> . 2021;118(33):e2100295118. doi:10.1073/pnas.2100295118
312 313 314	13.	Sasawatari S, Okamura T, Kasumi E, et al. The solute carrier family 15A4 regulates TLR9 and NOD1 functions in the innate immune system and promotes colitis in mice. <i>Gastroenterology</i> . 2011;140(5):1513-1525. doi:10.1053/j.gastro.2011.01.041
315 316 317	14.	Katewa A, Suto E, Hui J, et al. The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. <i>PloS one</i> . 2021;16(1):e0244439. doi:10.1371/journal.pone.0244439

318 319 320 321	15.	Zárate N, Mearin F, Wang X-Y, Hewlett B, Huizinga JD, Malagelada J-R. Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. <i>Gut.</i> 2003;52(7):966-970. doi:10.1136/gut.52.7.966
322 323 324	16.	Carlin JL, Lieberman VR, Dahal A, et al. Efficacy and Safety of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial. <i>Gastroenterology</i> . 2021;160(1):76-87.e4. doi:10.1053/j.gastro.2020.07.029
325 326	17.	Initiative C-19 HG. Mapping the human genetic architecture of COVID-19. <i>Nature</i> . 2021. doi:10.1038/s41586-021-03767-x
327 328 329	18.	Purcell S, Neale B, Todd-Brown K, et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. <i>The American Journal of Human Genetics</i> . 2007;81(3):559-575. doi:10.1086/519795
330		
331		
332		
333		
334		
335		
336		
337		
338		
339		
340		
341		
342		
343		
344		
345		
346		
347 348	Table patien	1. Demographics and clinical characteristics of the screened cohort of gastroparesis ts
349	Table	2. Top GWAS variants for idiopathic cases versus controls
350	Table	3. Top GWAS variants for diabetic cases versus idiopathic cases

- Figure 1. Manhattan plots showing top results for A. GWAS: idiopathic gastroparesis versus
- 352 controls B. GWAS: diabetic gastroparesis cases versus controls
- Figure 2. Zoom plot showing *SLC15A4* rs33990080 variant of region detected in the idiopathic
- 354 gastroparesis cases versus matched controls analysis
- 355
- 356
- 357
- 358
- 359 360
- gnomAD_genome_NFE gnomAD_genome_ALL **DR. idio.vs. cont** MAF.nongastro MAF.gastro.all Nearest Gene P. idio. vs. cont AAChange MAF.diab MAF.idio dbSNP Type At Ę å 2 70575204 A C intergenic FAM136A, TGFA rs10203624 0.51 5.08E-06 0.200 0.154 0.169 0.260 0.318 0.265 2 150783253 G A intergenic LINC01931,LINC01817 rs11689526 0.57 6.00E-06 0.400 0.271 0.314 0.385 0.316 0.377 4 168501627 G T intergenic rs1904115 1.67 9.16E-06 0.171 0.341 0.285 0.230 0.229 0.239 SPOCK3.ANXA10 8 40159237 T C intergenic C8orf4,ZMAT4 rs16889111 2.58 8.28E-06 0.033 0.093 0.074 0.040 0.053 0.047 1320866 A G intergenic DMRT2, SMARCA2 rs72687269 4.23 8.37E-06 0.010 0.047 0.034 0.013 0.010 0.016 9 11 24192805 C G intergenic MIR8054,LUZP2 rs2403906 1.89 1.14E-06 0.186 0.269 0.241 0.166 0.210 0.211 12 129297153 G A intronic rs10847696 1.99 4.13E-06 0.114 0.189 0.165 0.101 0.092 0.092 SI C 1 5 A 4 12 129299446 A G exonic SLC15A4 NM_145648:exon2:c.T716C:p.V239A rs33990080 2.01 4.81E-06 0.100 0.182 0.155 0.096 0.065 0.089 57217671 С Т intronic CCBE1 rs 72 27 690 3.43 7.60E-06 0.024 0.061 0.049 0.021 0.037 0.022 18 19 31224845 C T intergenic ZNF536,LINC01791 rs142557503 6.28 7.92E-06 0.029 0.035 0.033 0.006 0.009 0.015

362 Table 2

363

chr	đ	Ref	Alt	Type	Nearest Gene	ExonicFunc	dhSNP	OR.logit.diab.vs.idio	P.logit.diab.vs.idio	MAF.diab	MAF.idio	MAF-gastro-all	MAF.nongastro	gnomAD_genome_ALL	gnom AD_genome_NFE
2	72416952	тстс	-	intronic	EXOC6B		rs139115191	3.36	1.45E-07	0.291	0.122	0.177	0.184	0.115	0.164
2	114998082	G	С	intergenic	LINC01191, DPP10	,	rs3132039	3.34	6.09E-06	0.229	0.096	0.140	0.120	0.090	0.129
6	32698988	А	С	intergenic	HLA-DQB1,HLA-DQA2	,	rs7751856	3.03	1.26E-07	0.610	0.435	0.492	0.462	0.489	0.540
6	32729642	С	G	exonic	HLA-DQB2	synonymous SNV	rs762815	2.5	3.45E-06	0.55	0.4	0.45	0.41	0.66	0.57
11	95405933	С	Т	intergenic	LOC100129203,FAM76B	,	rs7931781	2.40	3.08E-06	0.595	0.409	0.470	0.479	0.561	0.538
12	2964735	G	А	ncRNA_intronic	LOC100507424	,	rs7138715	2.86	3.55E-06	0.286	0.143	0.190	0.191	0.263	0.176
15	78567853	G	Т	exonic	DNAJA4	synonymous SNV	rs967821	2.79	1.15E-05	0.286	0.150	0.194	0.175	0.212	0.193

365 Table 3

366

364

367









377